Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

被引：0
|
作者：
Wolchok, Jedd D.
Chiarion-Sileni, Vanna
Gonzalez, Rene
Rutkowski, Piotr
Grob, Jean Jacques
Cowey, Charles Lance
Lao, Christopher D.
Schadendorf, Dirk
Ferrucci, Pier Francesco
Smylie, Michael
Dummer, Reinhard
Hill, Andrew Graham
Haanen, John B. A. G.
Maio, Michele
McArthur, Grant A.
Yang, Arvin
Rollin, Linda
Horak, Christine E.
Larkin, James M. G.
Hodi, F. Stephen
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
[3] Oncol Inst Veneto IRCCS, Padua, Italy
[4] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
[5] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[6] Inst Oncol, Warsaw, Poland
[7] Hosp Timone, Marseille, France
[8] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[9] Univ Michigan, Ann Arbor, MI 48109 USA
[10] Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany
[11] European Inst Oncol, Milan, Italy
[12] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[13] Univ Spital Zurich, Zurich, Switzerland
[14] Tasman Oncol Res, Southport, Qld, Australia
[15] Netherlands Canc Inst, Amsterdam, Netherlands
[16] Univ Hosp Siena, Siena, Italy
[17] Peter MacCallum Canc Ctr, East Melbourne, Australia
[18] Bristol Myers Squibb Co, Princeton, NJ USA
[19] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[20] Royal Marsden Hosp, London SW3 6JJ, England
[21] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA1
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915).
    Long, Georgina V.
    Schadendorf, Dirk
    Del Vecchio, Michele
    Larkin, James
    Atkinson, Victoria
    Schenker, Michael
    Pigozzo, Jacopo
    Gogas, Helen J.
    Dalle, Stephane
    Meyer, Nicolas
    Ascierto, Paolo A.
    Sandhu, Shahneen
    Eigentler, Thomas
    Gutzmer, Ralf
    Hassel, Jessica C.
    Robert, Caroline
    Carlino, Matteo
    Di Giacomo, Anna Maria
    Butler, Marcus O.
    Munoz-Couselo, Eva
    Brown, Michael P.
    Rutkowski, Piotr
    Haydon, Andrew
    Grob, Jean-Jacques
    Schachter, Jacob
    Queirolo, Paola
    Menzies, Alexander
    Re, Sandra
    Bas, Tuba O.
    de Pril, Veerle
    Tenney, Daniel
    Tang, Hao
    Weber, Jeffrey S.
    CANCER RESEARCH, 2021, 81 (13)
  • [22] Quality-adjusted survival of combined nivolumab plus ipilimumab (NIVO plus IPI) or NIVO alone vs IPI among treatment-naive patients (pts) with advanced melanoma (MEL): a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
    Botteman, M.
    Shah, R.
    Gupte-Singh, K.
    Luo, L.
    Sabater, J.
    Rao, S.
    McDermott, D. F.
    Atkins, M. B.
    Regan, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Haanen, John B. A. G.
    Espinosa, Enrique
    Demidov, Lev V.
    Garbe, Claus
    Lorigan, Paul
    Gogas, Helen
    Hoeller, Christoph
    Guren, Tormod Kyrre
    Rorive, Andree
    Rutkowski, Piotr
    Munoz-Couselo, Eva
    Dummer, Reinhard
    Carneiro, Ana
    Hospers, Geke
    Grigoryeva, Elena Borisovna
    Bhore, Rafia
    Nathan, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067
    Hodi, F. Stephen
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Rutkowski, Piotr
    Lao, Christopher D.
    Cowey, Charles Lance
    Schadendorf, Dirk
    Wagstaff, John
    Dummer, Reinhard
    Queirolo, Paola
    Smylie, Michael
    Butler, Marcus O.
    Hill, Andrew Graham
    Marquez-Rodas, Ivan
    Ritchings, Corey
    Sakkal, Leon A.
    Wang, Peter
    Wolchok, Jedd D.
    Larkin, James
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma (MEL): Results of a phase III study (CheckMate 066)
    Long, Georgina V.
    Atkinson, Victoria
    Ascierto, Paolo Antonio
    Robert, Caroline
    Hassel, Jessica Cecile
    Rutkowski, Piotr
    Savage, Kerry J.
    Taylor, Fiona
    Coon, Cheryl
    Gilloteau, Isabelle
    Dastani, Homa
    Waxman, Ian
    Abernethy, Amy Pickar
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naive advanced melanoma (MEL): results of a phase III study (CheckMate 066)
    Long, G. V.
    Atkinson, V.
    Ascierto, P. A.
    Robert, C.
    Hassel, J. C.
    Rutkowski, P.
    Savage, K. J.
    Taylor, F.
    Coon, C.
    Gilloteau, I.
    Dastani, H. B.
    Waxman, I.
    Abernethy, A. P.
    ANNALS OF ONCOLOGY, 2015, 26 : 27 - 28
  • [27] Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.
    Hodi, F. Stephen
    Postow, Michael Andrew
    Chesney, Jason Alan
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth F.
    McDermott, David F.
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser F.
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April
    Taylor, Matthew Hiram
    Ott, Patrick Alexander
    Horak, Christine E.
    Gagnier, Paul
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO plus IPI) combination therapy in advanced melanoma
    Larkin, J. M. G.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Rutkowski, P.
    Lao, C.
    Cowey, C. L.
    Schadendorf, D.
    Wagstaff, J.
    Dummer, R.
    Ferrucci, P. F.
    Smylie, M.
    Hogg, D.
    Hill, A.
    Marquez-Rodas, I.
    Haanen, J. B. A. G.
    Rizzo, J.
    Balogh, A.
    Hodi, F. S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 904 - 905
  • [29] PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
    Long, G. V.
    Larkin, J.
    Ascierto, P. A.
    Hodi, F. S.
    Rutkowski, P.
    Sileni, V.
    Hassel, J.
    Lebbe, C.
    Pavlick, A. C.
    Wagstaff, J.
    Schadendorf, D.
    Dummer, R.
    Hogg, D.
    Haanen, J. B. A. G.
    Corrie, P.
    Hoeller, C.
    Horak, C.
    Wolchok, J.
    Robert, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069).
    Hodi, F. Stephen
    Postow, Michael Andrew
    Chesney, Jason Alan
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth F.
    McDermott, David F.
    Linette, Gerald P.
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv
    Shaheen, Montaser F.
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April K.
    Taylor, Matthew H.
    Ott, Patrick Alexander
    Jiang, Joel
    Gagnier, Paul
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345